HCM-related 5-year survival rate was 94% and HCM-related 5-year event-free rate was 80% in an unselected cohort of Japanese patients with hypertrophic cardiomyopathy.
Cohort (n=293)
Yes
In an aged Japanese community cohort, HCM mortality was favorable but 20% of patients experienced HCM-related adverse cardiovascular events within 5 years, with NYHA class III, AF, lower fractional shortening, and LVOTO being significant predictors.
In our unselected registry in an aged Japanese community, HCM mortality was favorable, but one-fifth of the patients commonly suffered from HCM-related adverse cardiovascular events during the 5-year follow-up period. Careful management of HCM patients is needed, particularly for those with the above-mentioned clinical determinants.
Kubo et al. (Mon,) conducted a cohort in Hypertrophic Cardiomyopathy (n=293). HCM-related 5-year survival rate was 94% and HCM-related 5-year event-free rate was 80% in an unselected cohort of Japanese patients with hypertrophic cardiomyopathy.